Drug intelligence / Profile preview

89Zr-DFO-BfAb

Development stage: Preclinical
Lead developer: GSK
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
Administration: Intravenous

Overview

89Zr-DFO-BfAb is an experimental Zirconium-89 (89Zr) labeled bifunctional antibody (BfAb) conjugated with the hexadentate chelator desferrioxamine (DFO). Developed by GSK, it is designed as an immuno-PET imaging agent to evaluate the in vivo biodistribution, pharmacokinetics, and targeting of bifunctional antibodies. Bifunctional antibodies are a class of biotherapeutics that bind to two different epitopes or antigens, offering therapeutic advantages such as mediating effector cells to kill tumor cells. Radiolabeling with 89Zr allows for non-invasive, whole-body PET/CT and PET/MR imaging to optimize the development of these biotherapeutics.

Other names: 89Zr-DFO-BfAb

Beyond the preview

Go deeper on 89Zr-DFO-BfAb.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 89Zr-DFO-BfAb.